title: Prevalence and treatment patterns of psoriatic arthritis in the UK.
abstract: OBJECTIVE
  The objectives of this study were to determine the prevalence of PsA in The Health Improvement Network (THIN), a large population-based medical records database in the UK, to examine factors associated with prevalent PsA among patients with psoriasis and to describe the use of DMARDs in patients with PsA.
  
  
  METHODS
  Two cohorts were derived from THIN to examine the prevalence of PsA in a cross-sectional study among all patients aged 18-90 years and among a subcohort of 4900 psoriasis patients aged 45-65 years. Prescription codes were used to describe therapies after the diagnosis of PsA. Associations for prevalent PsA among psoriasis patients were assessed using logistic regression analysis.
  
  
  RESULTS
  Among 4.8 million patients in THIN between the ages of 18 and 90 years, 9045 patients had at least one medical code for PsA, giving an overall prevalence of 0.19% (95% CI 0.19%, 0.19%). Of those patients, 45.9% with PsA have been prescribed DMARDs. Among the 4064 confirmed psoriasis patients, the prevalence of PsA was 8.6% (95% CI 7.7%, 9.5%). PsA was more prevalent among patients with severe psoriasis [odds ratio (OR) 3.34; 95% CI 2.40, 4.65], obesity (OR 1.77; 95% CI 1.30, 2.41) and duration of psoriasis for ≥10 years (OR 7.42; 95% CI 3.86, 14.25) in the fully adjusted model.
  
  
  CONCLUSIONS
  The prevalence of PsA in THIN is consistent with previous population-based estimates. Limitations include a definition of PsA based on a diagnostic code rather than Classification Criteria for Psoriatic Arthritis (CASPAR) criteria. Given the large population of PsA patients, THIN is an important resource for the study of PsA.
authors.affiliation: Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 8 Penn Tower, 1 Convention Ave, Philadelphia, PA 19104, USA. alexis.ogdie@uphs.upenn.edu
authors.forename: Alexis
authors.initials: A
authors.lastname: Ogdie
authors.forename: Sinéad
authors.initials: S
authors.lastname: Langan
authors.forename: Thorvardur
authors.initials: T
authors.lastname: Love
authors.forename: Kevin
authors.initials: K
authors.lastname: Haynes
authors.forename: Daniel
authors.initials: D
authors.lastname: Shin
authors.forename: Nicole
authors.initials: N
authors.lastname: Seminara
authors.forename: Nehal N
authors.initials: NN
authors.lastname: Mehta
authors.forename: Andrea
authors.initials: A
authors.lastname: Troxel
authors.forename: Hyon
authors.initials: H
authors.lastname: Choi
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gelfand
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000453:epidemiology*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D057286:Electronic Health Records; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011565:Psoriasis / Q000453:epidemiology; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents